title: Should we target signal pathways instead of single mediators in the treatment of sepsis?
authors.affiliation: Clinical and Laboratory Research Department, Bellco SpA, Mirandola/MO, Italy. marylou.wratten@bellcospa.it
authors.forename: M L
authors.initials: ML
authors.lastname: Wratten
authors.forename: A
authors.initials: A
authors.lastname: Brendolan
authors.forename: C
authors.initials: C
authors.lastname: Ronco
authors.forename: G
authors.initials: G
authors.lastname: La Greca
authors.forename: C
authors.initials: C
authors.lastname: Tetta
mesh_terms: D000209:Acute-Phase Proteins; D002352:Carrier Proteins / Q000502:physiology; D015936:Complement C5a / Q000037:antagonists & inhibitors; D005609:Free Radicals; D006440:Hemofiltration; D006801:Humans; D008081:Liposomes / Q000378:metabolism; D008562:Membrane Glycoproteins; D016328:NF-kappa B / Q000502:physiology; D018805:Sepsis / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000099231:Lipopolysaccharide-Binding Protein
chemical_list: D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D015936:Complement C5a; D005609:Free Radicals; D008081:Liposomes; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D000099231:Lipopolysaccharide-Binding Protein